Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Aug 31;78(9):867-869.
doi: 10.1016/j.jacc.2021.07.002.

Low-Dose Colchicine for the Management of Coronary Artery Disease

Jean-Claude Tardif  1 , Guillaume Marquis-Gravel  2
Affiliations
Free article
Editorial

Low-Dose Colchicine for the Management of Coronary Artery Disease

Jean-Claude Tardif et al. J Am Coll Cardiol. .
Free article
No abstract available

Keywords: anti-inflammatory agents; atherosclerosis; cardiovascular inflammation; ischemic risk; myocardial infarction; secondary prevention.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Tardif has received grant support from Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Novartis, Pfizer, RegenXBio, and Sanofi; has received honoraria from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals, Pendopharm, and Sanofi; has minor equity interest in DalCor Pharmaceuticals; and is mentioned as an author on submitted patents on pharmacogenomics-guided CETP inhibition, use of colchicine after myocardial infarction, and use of colchicine in COVID-19 (he has waived his rights in the colchicine patents and does not stand to gain financially). Dr Marquis-Gravel has received research grants from Bayer; has received speaker honoraria from Novartis; and has served on national advisory boards for Servier, JAMP, and Bayer.

Comment on

LinkOut - more resources